Company Quick10K Filing
Integrity Applications
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 162 $57
10-Q 2019-11-13 Quarter: 2019-09-30
10-Q 2019-08-14 Quarter: 2019-06-30
10-Q 2019-05-15 Quarter: 2019-03-31
10-K 2019-04-15 Annual: 2018-12-31
10-Q 2018-11-14 Quarter: 2018-09-30
10-Q 2018-08-14 Quarter: 2018-06-30
10-Q 2018-05-15 Quarter: 2018-03-31
10-K 2018-03-30 Annual: 2017-12-31
10-Q 2017-11-14 Quarter: 2017-09-30
10-Q 2017-08-14 Quarter: 2017-06-30
10-Q 2017-05-15 Quarter: 2017-03-31
10-K 2017-03-31 Annual: 2016-12-31
10-Q 2016-11-14 Quarter: 2016-09-30
10-Q 2016-08-15 Quarter: 2016-06-30
10-Q 2016-05-16 Quarter: 2016-03-31
10-K 2016-03-30 Annual: 2015-12-31
10-Q 2015-11-16 Quarter: 2015-09-30
10-Q 2015-08-14 Quarter: 2015-06-30
10-Q 2015-05-15 Quarter: 2015-03-31
10-K 2015-03-31 Annual: 2014-12-31
10-Q 2014-11-14 Quarter: 2014-09-30
10-Q 2014-08-19 Quarter: 2014-06-30
10-Q 2014-05-13 Quarter: 2014-03-31
10-K 2014-03-28 Annual: 2013-12-31
10-Q 2013-11-14 Quarter: 2013-09-30
10-Q 2013-08-19 Quarter: 2013-06-30
10-Q 2013-05-20 Quarter: 2013-03-31
10-K 2013-04-01 Annual: 2012-12-31
10-Q 2012-08-14 Quarter: 2012-06-30
10-Q 2012-05-15 Quarter: 2012-03-31
10-K 2012-03-14 Annual: 2011-12-31
10-Q 2011-12-29 Quarter: 2011-09-30
8-K 2020-02-14 Enter Agreement, Sale of Shares
8-K 2019-11-20 Officers
8-K 2019-10-31 Officers, Exhibits
8-K 2019-10-25 Sale of Shares, Officers, Exhibits
8-K 2019-09-04 Officers
8-K 2019-08-02 Officers, Exhibits
8-K 2019-07-30 Officers
8-K 2019-07-08 Officers
8-K 2019-06-14 Enter Agreement, Sale of Shares
8-K 2019-03-26 Enter Agreement
8-K 2018-12-31 Other Events
8-K 2018-12-21 Shareholder Vote
8-K 2018-10-02 Officers
8-K 2018-07-25 Regulation FD, Exhibits
8-K 2018-03-23 Officers, Shareholder Vote, Exhibits
8-K 2018-03-07 Enter Agreement, Sale of Shares, Exhibits

Integrity Applications Financials

IGAP Metrics, Comps, Filings

Annual | Quarterly

Business

Incorporated in Delaware in May 2010, we are a medical device company focused on the design, development and commercialization of non-invasive glucose monitoring devices for use by people with diabetes and pre-diabetics. On July 15, 2010, we completed a reverse triangular merger with Integrity Israel and Integrity Acquisition Corp. Ltd., an Israeli corporation and a wholly owned subsidiary of ours, pursuant to which Integrity Acquisition Corp. Ltd. merged with and into Integrity Israel and all of the stockholders and option holders of Integrity Israel became entitled to receive shares and options in us in exchange for their shares and options in Integrity Israel (the “Reorganization”). Following the Reorganization, the former equity holders of Integrity Israel were entitled to the same proportional ownership in us as they had in Integrity Israel prior to the Reorganization. As a result of the Reorganization, Integrity Israel became a wholly owned subsidiary of ours. We operate primarily through Integrity Israel.

Integrity Israel was founded in 2001 with a mission to develop, produce and market non-invasive glucose monitors for home use by diabetics. We have developed a non-invasive glucose monitor, the GlucoTrack® model DF-F glucose monitoring device, which is designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, cost and difficulty of conventional (invasive) spot finger stick devices. The GlucoTrack® model DF-F utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid.

In June 2013, we received the initial Conformité Européene (CE) Mark (indicating the conformity of the Company's product with health, safety, and environmental protection standards for products sold within the European Economic Area) approval for the GlucoTrack® model DF-F non-invasive glucose monitoring device from DEKRA Certification B.V., our European notified body (the “Notified Body”), which is an entity that has been accredited by a member state of the European Union (“EU”) to assess whether a product to be placed on the market meets certain preordained standards.


Valuation ($MM)

Market Cap, Enterprise Value

Balance Sheet ($MM)

Assets, Stockholders' Equity

Income Statement ($MM Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($MM Annual)

Operating, Investing, Financing

Comps ($'000 TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
China Health Industries (CHHE) 58,986 76% 4.3 7% 45,755 8,572 9,275 7,037 3,307 5,434 23,478
Research Solutions (RSSS) 58,502 29% -59.4 -9% 10,413 7,382 28,794 8,343 -960 -894 53,149
Mateon Therapeutics (OXGN) 58,429 -18.9 -41% 7,660 2,043 0 0 -3,123 -3,095 58,345
Aerogrow (AERO) 58,358 34% -137.9 -4% 16,421 5,027 35,097 11,993 -714 -413 56,973
Ambase (ABCP) 57,848 -16.1 -21% 15,508 378 0 0 -3,275 -3,301 53,081
Insurance Acquisition (INSUU) 57,560 86.5 0% 152,445 6,708 0 0 476 658 56,885
Invo Bioscience (IVOB) 57,552 89% -49.4 -52% 3,396 6,555 1,128 1,003 -1,766 -1,110 54,889
Propel Media (PROM) 57,502 68% 2.6 24% 40,227 67,463 89,698 61,206 9,581 40,275 102,755
Green Spirit (GSRX) 57,344 55% -5.9 -44% 21,652 3,469 6,970 3,815 -9,530 -9,530 56,077
Protokinetix (PKTX) 57,289 -33.1 -231% 742 5 0 0 -1,717 -1,717 56,785
mCig (MCIG) 56,867 13% -48.9 -17% 10,017 2,692 1,942 251 -1,727 -1,156 56,487
Integrity Applications (IGAP) 56,681 0% 5.1 349% 3,055 3,040 136 0 10,648 10,648 54,350
Greenbox Pos (GRBX) 56,573 83% 392.4 3% 750 919 588 489 26 144 56,573
Highlands Bankshares (HBKA) 55,852 1.0 1% 611,721 551,690 0 0 3,690 8,460 8,097
Arch Therapeutics (ARTH) 55,545 -10.2 -136% 3,791 3,962 0 0 -5,155 -5,155 52,363
CTD Holdings (CTDH) 55,443 93% -9.0 -71% 7,591 2,751 958 894 -5,425 -5,425 48,836
Applied Energetics (AERG) 55,133 -16.6 -421% 797 2,151 0 0 -3,352 -3,314 55,033
Sansal Wellness Holdings (SSWH) 54,357 47% -8.6 -50% 12,580 1,172 5,758 2,724 -6,314 -5,986 51,317
Hoth Therapeutics (HOTH) 54,142 -23.8 -47% 4,428 239 0 0 -2,097 -2,097 49,850
Target Group (CBDY) 54,136 -11.6 -21% 21,520 6,926 0 0 -4,597 -4,515 52,358

Balance Sheet ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash1,8975432,3865,8286091495453
Accounts Receivable23189212223
Inventory848161,420957171
PP&E8370306122220240217150
Assets2,1828152,7566,3482,1332,4611,669688
Accounts Payable729781051,0831,6352,4202,064
Long-Term Debt
Liabilities1,2141,3189,4573,4322,1673,3694,8233,561
Stockholders' Equity968-503-11,063-4,832-6,971-10,949-16,575-2,873
Income Statement ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Revenue6014361258943
Cost of Revenue
Gross Profit
R&D1,7891,9211,9871,8502,2682,8823,2073,033
SG&A5448531,0411,8182,5301,1281,5253,549
Tax000000
Net Income-2,364-2,772-9,7972,980-5,842-5,410-10,3296,715
Cash Flow ($'000)2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash Operating-1,916-2,297-3,218-3,362-4,565-5,312-5,895-4,892
Cash Investing-40-18-104-92-203-76-19-5
Cash Financing2,3839545,0566,973-4614,9375,7514,962